Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Huya Bioscience International has entered into strategic partnership deal with the Tianjin Institute of Pharmaceutical Research (TIPR) to promote new drug development in China and worldwide.
Subscribe to our email newsletter
The collaborative agreement will combine both parties’ strengths in promoting the advancement of China’s drug innovations.
As per the partnership deal, Huya will have the first opportunity to evaluate certain research and development projects conducted at TIPR and to provide support and assistance as needed.
TIPR president Lida Tang hopes the alliance with Huya can help take TIPR-developed compounds to the next level in development, testing and commercialization.
TIPR consists of seven major research divisions, including a center for drug innovation, a Medicinal Chemistry Department, a Traditional Chinese Medicine Department, a Center for Pharmaceutical Formulation Technology and Engineering Support and a Center for Drug Evaluation.